GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a biotech company developing innovative RNA therapeutics. Its stock price is highly volatile, driven by news of clinical trials and partnerships with major pharmaceutical companies licensing its promising technologies.
Share prices of companies in the market segment - Pharma liver
Arrowhead is a biopharmaceutical company focused on RNA interference for the treatment of liver and other diseases. We classify it as part of the Pharma Liver sector, and the chart below shows the dynamics of this segment as a whole.
Broad Market Index - GURU.Markets
Arrowhead Pharmaceuticals is a biotech company pioneering RNA interference (RNAi), developing drugs that "switch off" disease-causing genes. As a component of the GURU.Markets index, it represents the cutting edge of medicine. The chart below represents the entire market. See how this innovator compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
ARWR - Daily change in the company's share price Arrowhead Pharmaceuticals
The daily price change of Arrowhead Pharmaceuticals, a company active in RNA interference, reflects the high volatility of the biotech sector. Change_co is an immediate reaction to clinical trial news. This indicator is indispensable for building risk models for innovative pharmaceutical companies on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma liver
Arrowhead Pharmaceuticals, Inc. is a biotech company. This chart highlights the sector's extreme volatility. Comparison with ARWR, a pioneer in RNA interference, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Arrowhead is a leader in RNA interference (RNAi), a new class of drugs. This is a cutting-edge and highly speculative area of biotech. The chart below illustrates the high volatility typical of this sector, reflecting the risks and potential associated with Arrowhead's technologies.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Arrowhead Pharmaceuticals
Arrowhead is a pioneer in RNAi-based drug development. Its year-over-year performance reflects both the commercial success of its drugs and investor confidence in its R&D platform, which is focused on new breakthrough drugs.
Annual dynamics of market capitalization of the market segment - Pharma liver
Arrowhead Pharmaceuticals, Inc. is a biotechnology company pioneering the development of targeted RNA therapies. Its innovative platform targets difficult-to-treat diseases. Its stock price reflects the high potential of its technology and the risks associated with clinical trials.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Arrowhead Pharmaceuticals is a biotech company whose fate depends on the success of its innovative RNA drugs. Its stock price is completely disconnected from economic cycles. Its chart reflects scientific events—news about clinical trials and partnerships—rather than macroeconomic data, making it a high-risk science bet.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Arrowhead Pharmaceuticals
Arrowhead, a biopharmaceutical company, depends on its RNA interference platform. The monthly fluctuations on the chart reflect not sales, but rather news about clinical trials of its drugs for liver and other diseases, the success of which determines the potential of its technology.
Monthly dynamics of market capitalization of the market segment - Pharma liver
Arrowhead Pharmaceuticals develops RNA interference-based drugs aimed at disabling genes that cause diseases, particularly liver disease. This is the cutting edge of gene therapy. The chart below reflects sentiment in the biotech sector, where investors are weighing the enormous potential of breakthrough technologies against the high risks.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Shares of biotech companies developing breakthrough technologies like RNA interference often move on trial news. The chart below shows the overall sentiment. Is Arrowhead Pharmaceuticals living its own life, or is its high beta causing it to exaggerate market movements?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops innovative RNA-based therapeutics, which carries high risks. Weekly fluctuations in the company's stock price are almost always a reaction to the publication of clinical trial data or regulatory decisions. The chart clearly demonstrates the volatility inherent in cutting-edge biotechnology.
Weekly dynamics of market capitalization of the market segment - Pharma liver
The RNA-based biotech sector, which includes Arrowhead, is riding a wave of scientific breakthroughs and setbacks. News in this field often impacts the entire niche. The chart below illustrates this general sentiment. It allows one to assess how cutting-edge the market considers Arrowhead's platform compared to competitors' technologies.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Arrowhead Pharmaceuticals develops drugs based on RNA interference, a cutting-edge technology in medicine. Its shares move not with the market, but on news about clinical trials. The chart clearly demonstrates how successes or failures in the lab cause fluctuations that defy overall trends.
Market capitalization of the company, segment and market as a whole
ARWR - Market capitalization of the company Arrowhead Pharmaceuticals
The Arrowhead Pharmaceuticals market capitalization chart visualizes the promise and risks of RNAi drug development. The sharp ups and downs on this chart are a direct reaction from investors to clinical trial data. The scale of its value reflects the market's faith in the potential of the company's platform for treating difficult-to-treat diseases.
ARWR - Share of the company's market capitalization Arrowhead Pharmaceuticals within the market segment - Pharma liver
Arrowhead Pharmaceuticals is a pioneer in the development of RNA interference (RNAi) therapies. Its market share reflects its leadership in this cutting-edge technology. The company's market capitalization reflects investors' valuation of its platform, which can "switch off" disease-causing genes.
Market capitalization of the market segment - Pharma liver
This chart shows the overall value of the biotech sector focused on liver diseases. For Arrowhead Pharmaceuticals, a pioneer in RNA interference, this line represents overall investor interest in this therapeutic area. The rising chart reflects hopes for the development of effective drugs for diseases such as hepatitis B and nonalcoholic steatohepatitis.
Market capitalization of all companies included in a broad market index - GURU.Markets
Arrowhead Pharmaceuticals develops drugs that "switch off" disease-causing genes. Its market cap is a bet on revolutionizing medicine. Compared to the overall market, its share demonstrates the enormous potential investors see in advanced gene technologies.
Book value capitalization of the company, segment and market as a whole
ARWR - Book value capitalization of the company Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops revolutionary RNA therapeutics, and its book value is the foundation for innovation. It consists of modern R&D centers, manufacturing facilities, and patents. Has the company increased its investment in its physical science capabilities? The chart below shows how this foundation has grown.
ARWR - Share of the company's book capitalization Arrowhead Pharmaceuticals within the market segment - Pharma liver
Arrowhead Pharmaceuticals develops RNA therapeutics, and its innovations are based on cutting-edge technology. The company invests in its own manufacturing facilities and laboratories to develop and manufacture complex drugs. The chart shows its share of the physical infrastructure required to create next-generation drugs.
Market segment balance sheet capitalization - Pharma liver
Arrowhead Pharmaceuticals is a pioneer in RNA interference. Pharmaceuticals, as the chart shows, are capital-intensive. Arrowhead, on the other hand, is a knowledge-intensive, asset-light company. Its capital comes not from factories, but from patents for a platform for "silencing" disease-causing genes.
Book value of all companies included in the broad market index - GURU.Markets
Arrowhead Pharmaceuticals creates the medicines of the future, building on a solid scientific foundation. The company's book value is derived from its advanced research centers, laboratories, and manufacturing facilities for creating RNA-based therapies. The chart shows the material foundation upon which innovations in the treatment of genetic diseases are built.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Arrowhead Pharmaceuticals
Arrowhead Pharma has labs, but the market is buying into its revolutionary RNA platform. The chart shows a huge "hope factor": how many times higher investors value the potential of its future drugs than all of its current assets. This is an investment in one of the most advanced technologies in medicine.
Market to book capitalization ratio in a market segment - Pharma liver
Arrowhead Pharmaceuticals develops RNA interference drugs to treat difficult-to-treat diseases. The company's value depends almost entirely on the success of its scientific platform. The chart illustrates the vast gap between market expectations and its modest tangible assets, typical of biotech.
Market to book capitalization ratio for the market as a whole
Arrowhead Pharmaceuticals develops innovative RNA interference drugs aimed at disabling disease-causing genes. The company's assets include its platform and patents. This chart shows the overall market valuation, but how do investors evaluate the potential of a biotechnology that could revolutionize the treatment of genetic diseases?
Debts of the company, segment and market as a whole
ARWR - Company debts Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is at the forefront of biotechnology, developing RNAi-based drugs. For the research-stage company, funding is everything. This chart illustrates how it uses various financial instruments to simultaneously advance several promising candidates through expensive clinical trials.
Market segment debts - Pharma liver
Arrowhead Pharmaceuticals develops drugs that use RNA interference to treat liver and other organ diseases. This is a cutting-edge, but very expensive, area of biotechnology. This chart shows how the company funds its expensive clinical trials compared to other innovative pharmaceutical companies.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops drugs using RNA interference technology to treat difficult-to-treat diseases. This chart shows the company's financial structure. For a cutting-edge biotech company that has yet to achieve stable profitability, capital and debt management are critical to funding lengthy and expensive clinical trials.
Market segment debt to market segment book capitalization - Pharma liver
Developing innovative RNA therapeutics, as Arrowhead does, requires massive and risky R&D investments. This chart illustrates how the biotech sector as a whole funds its research activities. It allows one to evaluate Arrowhead's financial model and its reliance on external capital compared to other companies in the pharmaceutical industry.
Debt to book value of all companies in the market
This chart shows the overall debt level for all companies in the market. Arrowhead, a biotech company in the R&D stage, relies on investor capital. The comparison with the broader market, dominated by profitable businesses, clearly demonstrates how different a financial model based on future scientific breakthroughs is from the traditional economy that generates profits today.
P/E of the company, segment and market as a whole
P/E - Arrowhead Pharmaceuticals
This chart for Arrowhead Pharmaceuticals, which develops RNAi drugs, reflects the lofty expectations of investors. Like many biotechs, its value is based not on current profits, but on faith in the breakthrough potential of the platform and the future success of clinical trials. This is the price paid for the opportunity to revolutionize disease treatment.
P/E of the market segment - Pharma liver
RNA interference drug development, the focus of Arrowhead, is at the cutting edge of pharmaceuticals. This chart shows the average valuation for biotech companies. It helps us understand that Arrowhead is valued as a scientific platform with enormous potential, and its value depends on the success of clinical trials across a wide range of diseases.
P/E of the market as a whole
Arrowhead Pharmaceuticals develops innovative RNA interference (RNAi) drugs targeting difficult-to-treat diseases, particularly liver disease. This chart reflects the overall risk appetite of biotech investors. It helps understand whether the ARWR valuation reflects faith in the company's breakthrough technology or whether it moves in line with overall sector sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops innovative RNA interference (RNAi) drugs to treat genetically determined diseases, particularly liver disease. This chart reflects the high investor expectations for its technology platform. Its dynamics reflect the market's assessment of the likelihood of clinical trial success and the future commercial potential of its innovative drugs.
%20P%2FE%20Arrowhead%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Arrowhead-Pharmaceuticals&v=1772680540887 "Chart of the company's future (projected) P/E Arrowhead Pharmaceuticals")
Future (projected) P/E of the market segment - Pharma liver
Arrowhead Pharmaceuticals develops innovative RNA interference therapies targeting difficult-to-treat diseases. This chart shows how analysts estimate its future revenue compared to other biopharmaceutical companies, reflecting their confidence in the potential of its cutting-edge scientific platform.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-liver&v=1772680540924 "Future (projected) P/E graph of the market segment - Pharma liver")
Future (projected) P/E of the market as a whole
Arrowhead Pharmaceuticals develops innovative RNA interference (RNAi) drugs for the treatment of liver and other diseases. It is a high-risk biotech business. Its valuation depends not on general market forecasts, but on investor confidence in the scientific platform and the success of clinical trials.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772680540978 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops innovative RNA interference (RNAi) drugs for the treatment of liver and other diseases. The company's financial results tell a story of high R&D expenditures and royalties from major pharmaceutical partners. This chart shows the company's path to profitability through successful clinical trials and the commercialization of its platform.
Profit of companies in the market segment - Pharma liver
Arrowhead Pharmaceuticals develops innovative RNA interference (RNAi) drugs to treat difficult-to-treat diseases. This is a cutting-edge field of biotechnology. The profit dynamics in this sector, shown in the graph, demonstrate the potential of breakthrough technologies, where a single successful drug can dramatically transform a company's financial position.
Overall market profit
Arrowhead Pharmaceuticals is developing RNA interference drugs. This is a cutting-edge field of biotechnology that requires massive investment. The overall investment climate, which is indirectly reflected in this corporate earnings chart, is critically important. During periods of optimism, investors are more willing to fund risky research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is developing revolutionary RNA interference (RNAi) drugs that can "switch off" disease-causing genes. This represents the cutting edge of gene therapy. This graph reflects analyst consensus estimates, which are essentially a bet on the success of clinical trials and commercialization of this breakthrough technology.
%20profit%20of%20the%20company%20Arrowhead%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Arrowhead-Pharmaceuticals&v=1772680541263 "Graph of future (projected) profit of the company Arrowhead Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Pharma liver
Arrowhead Pharmaceuticals develops innovative RNA interference (RNAi) therapies for difficult-to-treat diseases, including liver disease. The company's future depends on the success of its cutting-edge scientific platform. This chart reflects profitability expectations for the biotech sector, providing insight into overall investor sentiment regarding breakthrough therapies.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-liver&v=1772680541285 "Graph of future (predicted) profits of companies in a market segment - Pharma liver")
Future (predicted) profit of the market as a whole
Arrowhead Pharmaceuticals is a biotech company developing RNA interference-based drugs. Its future depends on the success of clinical trials and the commercialization of its developments, not on economic cycles. Investors in such companies are more likely to follow scientific publications and regulatory updates than the overall corporate earnings forecast.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772680541318 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Arrowhead Pharmaceuticals
Arrowhead develops drugs based on RNA interference technology. For a biotech company with an innovative platform, this chart looks to the future. It shows the enormous value the market places on the potential future revenues of its developments, assessing the success of the entire platform.
P/S market segment - Pharma liver
Arrowhead Pharmaceuticals develops RNA interference (RNAi) therapeutics for the treatment of difficult-to-treat diseases. This chart displays the average revenue estimate in the biotech sector. It provides insight into how highly investors value the potential future revenue from Arrowhead's innovative platform, which aims to silence disease-causing genes.
P/S of the market as a whole
Arrowhead Pharmaceuticals develops RNA interference-based drugs for the treatment of difficult-to-treat diseases, particularly liver disease. Their technology promises to revolutionize medicine. This chart provides a general revenue benchmark against which to judge the enormous expectations investors have for ARWR's breakthrough scientific platform.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops innovative RNA interference (RNAi) drugs for the treatment of difficult-to-treat diseases. This chart reflects investors' high expectations for its future sales. This valuation is based on the potential of its technology platform to create a new class of drugs and success in clinical trials.
%20P%2FS%20Arrowhead%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Arrowhead-Pharmaceuticals&v=1772680541410 "The graph of the company's future (projected) P/S Arrowhead Pharmaceuticals")
Future (projected) P/S of the market segment - Pharma liver
Arrowhead Pharmaceuticals develops drugs that silence genes that cause difficult-to-treat diseases using RNA interference technology. This is at the cutting edge of science. This chart compares the risky but potentially enormous sales expectations for its drugs with those for the innovative biotech sector.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20liver&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-liver&v=1772680541454 "Future (projected) P/S market segment graph - Pharma liver")
Future (projected) P/S of the market as a whole
Arrowhead Pharmaceuticals develops innovative RNA interference drugs for the treatment of liver and other diseases. This chart reflects investors' appetite for risk and innovation. During periods when the market expects growth, investors are more inclined to invest in biotech companies with breakthrough but not yet fully commercialized potential, like Arrowhead.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772680541481 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops innovative drugs using RNA interference technology to "knock out" disease-causing genes. This chart reflects revenues that can come from partnerships with major pharmaceutical companies and licensing fees for the use of their platform. It illustrates the financial side of cutting-edge scientific research.
Sales of companies in the market segment - Pharma liver
Arrowhead Pharmaceuticals develops innovative RNA interference (RNAi) drugs targeting difficult-to-treat diseases, particularly liver disease. Its pipeline can be segmented by specific drugs or therapeutic areas. This chart displays the funding flows associated with one of these areas, demonstrating its progress.
Overall market sales
Arrowhead Pharmaceuticals develops innovative RNA interference therapies for the treatment of intractable diseases. The company's success depends on scientific breakthroughs, not short-term economic fluctuations. It represents the biotechnology sector that is creating future growth drivers for the healthcare economy by addressing humanity's fundamental challenges.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops RNA interference (RNAi)-based drugs to treat difficult-to-treat diseases by targeting their genetic causes. Future sales projections reflect market expectations for the success of its clinical programs, particularly in liver disease, and potential partnerships with major pharmaceutical companies.
%20sales%20of%20the%20company%20Arrowhead%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Arrowhead-Pharmaceuticals&v=1772680541572 "Schedule of future (projected) sales of the company Arrowhead Pharmaceuticals")
Future (projected) sales of companies in the market segment - Pharma liver
Arrowhead Pharmaceuticals develops innovative RNA interference drugs to treat difficult-to-treat diseases. This chart reflects revenue expectations for the biotech sector. It helps analysts understand the commercial potential and pace of adoption of new technologies in medicine, forming an investment framework for the entire industry.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-liver&v=1772680541584 "Schedule of future (projected) sales of companies in the market segment - Pharma liver")
Future (projected) sales of the market as a whole
Arrowhead Pharmaceuticals develops innovative RNA therapeutics. The biotech's success depends on investment in the sector and the market's willingness to accept new, expensive therapies. This chart of overall sales forecasts reflects the state of the economy, which impacts venture capital funding and healthcare budgets.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772680541587 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops innovative RNA interference (RNAi) drugs for the treatment of difficult-to-treat diseases, including liver disease. The company is at the forefront of biotechnology. This chart reflects its financial position, where significant investments in research and development currently outweigh revenue, paving the way for future profitability.
Market segment marginality - Pharma liver
Arrowhead Pharmaceuticals develops RNA interference (RNAi) therapeutics targeting difficult-to-treat diseases, particularly liver disease. This is a cutting-edge scientific platform with enormous potential. The chart illustrates how investments in breakthrough technologies can translate into operational efficiencies if developments are successful.
Market marginality as a whole
Arrowhead Pharmaceuticals develops innovative RNA interference drugs for the treatment of difficult-to-treat diseases. The company is at the forefront of biotechnology. This chart shows the profitability of mature businesses, while ARWR's primary value lies in its scientific platform and the potential for future medicines to transform medicine.
Employees in the company, segment and market as a whole
Number of employees in the company Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops RNA interference-based drugs for the treatment of difficult-to-treat diseases. This chart shows the growth of its scientific team. The increase in this intellectual capital is a direct indicator of progress in clinical trials and the expansion of its pipeline of promising developments.
Share of the company's employees Arrowhead Pharmaceuticals within the market segment - Pharma liver
Arrowhead Pharmaceuticals develops drugs based on RNA interference, a cutting-edge field of genetics. Progress here depends on attracting top scientists. This chart shows its human capital footprint in the gene therapy niche, reflecting its investment in talent to create next-generation drugs.
Number of employees in the market segment - Pharma liver
Arrowhead Pharmaceuticals develops innovative RNA interference drugs targeting liver and other organ diseases. This chart reflects employment in the biotech sector. The growing number of scientists in this field indicates active investment in breakthrough genetic technologies, creating a scientific and financial environment conducive to the success of Arrowhead's research.
Number of employees in the market as a whole
Arrowhead Pharmaceuticals is developing innovative RNAi drugs. For the biotech company, a strong economy, symbolized by job growth in this chart, creates a favorable investment climate. This allows it to attract capital for expensive clinical trials and bring life-changing drugs to market.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Arrowhead Pharmaceuticals (ARWR)
Arrowhead Pharmaceuticals develops drugs based on RNA interference, a cutting-edge technology in medicine. The astronomically high market capitalization per employee, visible in this chart, suggests that investors are evaluating the potential of its scientific platform, not current revenue. Each scientist at the company represents intellectual capital worth millions.
%20of%20the%20company%20Arrowhead%20Pharmaceuticals%20(ARWR)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Arrowhead-Pharmaceuticals-ARWR&v=1772680541875 "Chart of market capitalization per employee (in thousands of dollars) of the company Arrowhead Pharmaceuticals (ARWR)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma liver
Arrowhead (ARWR) is a biotech company specializing in RNA interference (RNAi), a gene silencing technology. Its value lies in its R&D platform. This chart shows the market value assigned to each elite scientist, not its current operations.
%20by%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-liver&v=1772680541893 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma liver")
Market capitalization per employee (in thousands of dollars) for the overall market
Arrowhead Pharmaceuticals develops drugs that use RNA interference to "switch off" disease-causing genes. This is a cutting-edge scientific platform with enormous potential. The chart illustrates the high market premium placed on revolutionary R&D, where a small team of scientists can transform medicine.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772680541931 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Arrowhead Pharmaceuticals (ARWR)
Arrowhead Pharmaceuticals is a biotech company developing RNA interference (RNAi) therapeutics targeting difficult-to-treat diseases, primarily liver diseases. This chart, typical for biotech, reflects not operating profits but rather the efficiency of R&D spending. It shows how the company leverages its highly skilled research staff to advance candidates through clinical trials.
%20Chart%20Arrowhead%20Pharmaceuticals%20(ARWR)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Arrowhead-Pharmaceuticals-ARWR&v=1772680541950 "Company Profit Per Employee (in thousands of dollars) Chart Arrowhead Pharmaceuticals (ARWR)")
Profit per employee (in thousands of dollars) in the market segment - Pharma liver
Arrowhead is an R&D company pioneering RNA interference (RNAi) technology for knocking out bad genes. This graph shows the benchmark for "Pharma liver" (Biotech). In this R&D sector, the benchmark is likely *negative*. Companies burn billions on R&D. Profit per scientist is a distant goal.
%20in%20the%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-liver&v=1772680541975 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma liver")
Profit per employee (in thousands of dollars) for the market as a whole
Arrowhead Pharmaceuticals (ARWR) is a biotech company developing RNA interference (RNAi)-based drugs. Their platform aims to "knock out" genes that cause liver and other organ diseases. This graph, showing average profit per employee, is important for biotech. It allows us to assess how much a sector where a handful of scientists can create a breakthrough drug outperforms the "average" labor efficiency.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772680541999 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Arrowhead Pharmaceuticals (ARWR)
Arrowhead Pharmaceuticals is developing RNA interference-based drugs to treat difficult-to-treat diseases. This graph illustrates the potential of its platform. If successful, a small team of scientists could create products generating billions in revenue, leading to explosive growth in revenue per employee.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Arrowhead-Pharmaceuticals-ARWR&v=1772680542028 "Sales chart per company employee Arrowhead Pharmaceuticals (ARWR)")
Sales per employee in the market segment - Pharma liver
Arrowhead Pharmaceuticals is a biotech company developing RNA interference (RNAi)-based drugs for the treatment of difficult-to-treat diseases, including liver disease. This chart shows revenue per employee. Since the company relies heavily on R&D and partnerships, comparing this to the segment shows how effective their scientific platform is in generating revenue (e.g., from licensing).
Sales per employee for the market as a whole
Arrowhead Pharmaceuticals is a biotech company developing RNA interference (RNAi)-based drugs. Rather than selling finished drugs, they build a platform and enter into major partnerships with giants like J&J and Takeda. Revenue comes primarily from upfront and milestone payments from partners. This chart shows the value (revenue) generated by their R&D team.
Short shares by company, segment and market as a whole
Shares shorted by company Arrowhead Pharmaceuticals (ARWR)
Arrowhead Pharmaceuticals develops drugs using cutting-edge RNA interference (RNAi) technology to "knock out" disease-causing genes. It's a breakthrough but risky approach. The company's success hinges on the outcome of clinical trials. This chart shows the number of skeptics betting the technology won't prove effective or safe.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Arrowhead-Pharmaceuticals-ARWR&v=1772680542115 "Short Shares Chart for the Company Arrowhead Pharmaceuticals (ARWR)")
Shares shorted by market segment - Pharma liver
Arrowhead Pharmaceuticals develops drugs using RNA interference (RNAi) technology to "knock out" disease-causing genes, with a focus on the liver. This is a groundbreaking but risky area of biotechnology. This chart shows the bets against the entire gene therapy sector, reflecting the high investor skepticism regarding long-term safety and efficacy.
Shares shorted by the overall market
Arrowhead (ARWR) is a biotech focused on RNA interference. This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and dump risk, especially unprofitable biotechs dependent on financing. This pessimism, visible on the chart, threatens the capital required by ARWR.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Arrowhead Pharmaceuticals (ARWR)
Arrowhead Pharmaceuticals is a pioneer in the development of RNA interference (RNAi) therapies. Its stock is extremely sensitive to trial news. This ARWR chart can soar above 70 on positive R&D data. A range below 30 often reflects research setbacks or general risk aversion in biotech.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Arrowhead-Pharmaceuticals-ARWR&v=1772680542207 "RSI 14 indicator chart for the company's stock Arrowhead Pharmaceuticals (ARWR)")
RSI 14 Market Segment - Pharma liver
Arrowhead (ARWR) is a disease silencer. The biotech company is a pioneer in RNA interference (RNAi), a technology that disables harmful genes. This chart shows the overall sentiment in the biotech sector. It helps us understand: is ARWR oversold due to an R&D failure or is there a general crisis of confidence in the entire RNAi sector?
RSI 14 for the overall market
Arrowhead Pharmaceuticals (ARWR) develops RNA interference-based drugs. For them, this chart is the pulse of biotech investors. When the market is overbought, it means investors are willing to take risks for ARWR's breakthrough technologies. When the market is oversold and fear-ridden, funding expensive research becomes nearly impossible.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ARWR (Arrowhead Pharmaceuticals)
Arrowhead Pharmaceuticals is a biotech company developing RNA interference (RNAi)-based drugs. Their technology silences genes responsible for disease development, often targeting the liver. This chart represents analyst consensus. Their forecasts are based on clinical trial data, potential partnerships with major pharma, and market assessments for their targeted drugs.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ARWR-Arrowhead-Pharmaceuticals&v=1772680542356 "A chart showing analyst consensus forecasts for the expected stock price. ARWR (Arrowhead Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price ARWR (Arrowhead Pharmaceuticals)
Arrowhead (ARWR) is a biotech company using a cutting-edge RNAi (RNA interference) platform to knock out disease-causing genes, with a focus on the liver. This chart demonstrates their belief in their science. It measures the gap between the price and the consensus target, reflecting the enormous potential analysts see in their R&D pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ARWR-Arrowhead-Pharmaceuticals&v=1772680542381 "A chart showing the difference between the consensus forecast and the actual stock price. ARWR (Arrowhead Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Pharma liver
Arrowhead is a biotech company at the forefront of RNA interference (RNAi). It develops drugs that "switch off" disease-causing genes, with a focus on the liver. This chart shows analysts' overall expectations for the liver pharma sector, reflecting whether experts believe this complex technology can deliver breakthroughs.
Analysts' consensus forecast for the overall market share price
Arrowhead Pharmaceuticals develops innovative RNA interference (RNAi) drugs that disable disease-causing genes, with a focus on the liver and lungs. This chart shows the overall market risk appetite. For Arrowhead, a biotech company whose value is based on future success, overall market optimism is critical to funding lengthy and expensive clinical trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a biotech company at the forefront of RNA interference (RNAi). Their platform (TRiM) enables the knockout of specific genes responsible for diseases, primarily in the liver. This chart is an assessment of their scientific platform. It reflects not their sales, but the potential of their R&D pipeline and their ability to forge major partnerships with pharma giants.
AKIMA Market Segment Index - Pharma liver
Arrowhead is a biotech pioneer and a leader in RNA interference (RNAi) technology (like Alnylam). The company uses its TRiM R&D platform to create targeted drugs that disable harmful genes. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does Arrowhead's futuristic RNAi platform differentiate it from the average pharma company?
The AKIM Index for the overall market
Arrowhead is a biotech company, a pioneer in RNAi therapy, a technology that allows for the knockout of genes that cause disease (especially liver disease). It's a high-risk bet. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this speculative scientific story compares to overall economic trends.
